- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.10. | Alto shares double on plans to speed depression drug's development | ||
| 20.10. | Mark Cuban says Cost Plus Drugs will partner with TrumpRx | ||
| 20.10. | AstraZeneca, Daiichi's Datroway excels in hard-to-treat breast cancer | ||
| 20.10. | Summit's dual-acting drug scores lung cancer win | ||
| 20.10. | Exelixis shares dip on colorectal cancer data | ||
| 20.10. | From weeks to minutes: How generative AI transforms pharma data and ROI | ||
| 20.10. | The self-perform edge: Fast, reliable construction for life sciences facilities | ||
| 20.10. | Accelerating clinical timelines with softgels: An on-demand approach that cuts weeks and costs | ||
| 17.10. | I-Mab morphs into 'hub-and-spoke' biotech; Astellas passes on Taysha gene therapy | ||
| 17.10. | FDA awards 9 companies a new 'national priority' voucher to speed drug reviews | ||
| 16.10. | A longshot bet on a tremor drug pays off | ||
| 16.10. | J&J claims success in study testing earlier Tecvayli use in multiple myeloma | ||
| 16.10. | Novartis confirms drug's benefits in rare kidney disease as competitors loom | ||
| 16.10. | California passes laws targeting PBMs, private equity | ||
| 15.10. | Novo wagers up to $2.1B on Omeros' rare disease drug | ||
| 15.10. | A regenerative therapy for hair loss attracts a mega-fundraising round | ||
| 15.10. | Lilly, battling skepticism, reinforces GLP-1 pill's case with new study data | ||
| 15.10. | [Podcast] The Progress Profile: Alzheimer's Research in Focus | ||
| 15.10. | Cancer drug startup Tubulis raises $361 million for ADCs | ||
| 14.10. | AstraZeneca cuts US drug pricing deal; FDA declares Novo plant out of compliance | ||
| 14.10. | Kailera nets $600M more to advance Zepbound-like obesity drug | ||
| 14.10. | BioCryst goes 'all in' on rare swelling disease with Astria deal | ||
| 14.10. | J&J plans to spin out orthopedics business | ||
| 13.10. | A young biotech nets $70M for a new type of allergy drug | ||
| 13.10. | Maximizing biomarker insights from minimal samples |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .